- Home
- BCTX vs RPID Comparison
BCTX vs RPID Comparison
Compare BCTX & RPID Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCTX
- RPID
- Stock Information
- Founded
- BCTX 2014
- RPID 2006
- Country
- BCTX Canada
- RPID United States
- Employees
- BCTX N/A
- RPID N/A
- Industry
- BCTX Biotechnology: Pharmaceutical Preparations
- RPID Medical Specialities
- Sector
- BCTX Health Care
- RPID Health Care
- Exchange
- BCTX Nasdaq
- RPID Nasdaq
- Market Cap
- BCTX 34.6M
- RPID 37.3M
- IPO Year
- BCTX N/A
- RPID 2021
- Fundamental
- Price
- BCTX $0.56
- RPID $0.90
- Analyst Decision
- BCTX Strong Buy
- RPID
- Analyst Count
- BCTX 1
- RPID 0
- Target Price
- BCTX $15.00
- RPID N/A
- AVG Volume (30 Days)
- BCTX 2.4M
- RPID 53.3K
- Earning Date
- BCTX 12-16-2024
- RPID 11-01-2024
- Dividend Yield
- BCTX N/A
- RPID N/A
- EPS Growth
- BCTX N/A
- RPID N/A
- EPS
- BCTX N/A
- RPID N/A
- Revenue
- BCTX N/A
- RPID $26,170,000.00
- Revenue This Year
- BCTX N/A
- RPID $24.34
- Revenue Next Year
- BCTX N/A
- RPID $19.49
- P/E Ratio
- BCTX N/A
- RPID N/A
- Revenue Growth
- BCTX N/A
- RPID 27.31
- 52 Week Low
- BCTX $0.46
- RPID $0.58
- 52 Week High
- BCTX $5.97
- RPID $1.34
- Technical
- Relative Strength Index (RSI)
- BCTX 38.43
- RPID 37.56
- Support Level
- BCTX $0.57
- RPID $0.97
- Resistance Level
- BCTX $0.66
- RPID $1.13
- Average True Range (ATR)
- BCTX 0.13
- RPID 0.07
- MACD
- BCTX -0.05
- RPID -0.01
- Stochastic Oscillator
- BCTX 0.00
- RPID 0.00
About BCTX BriaCell Therapeutics Corp.
BriaCell Therapeutics Corp is a clinical-stage immuno-oncology company. The group is developing an entirely new class of targeted immunotherapies to transform cancer care. Its product candidate Bria-IMT, is being evaluated in a pivotal Phase 3 combination study for metastatic breast cancer (MBC is breast cancer that has spread to other tissues). Bria-IMT is a targeted cell-based immunotherapy. The company is engaged in developing a Bria-OTS platform of personalized off-the-shelf cell-based immunotherapies. It is being evaluated in a Phase 1/2 clinical study and the treatment is initially focused on patients with breast cancer with an extension to prostate cancer, and other cancers.
About RPID Rapid Micro Biosystems Inc.
Rapid Micro Biosystems Inc is an life sciences technology company providing mission critical automation solutions to facilitate the efficient manufacturing and fast, safe release of healthcare products such as biologics, vaccines, cell and gene therapies, and sterile injectables. The company's flagship Growth Direct platform automates and modernizes the antiquated, manual microbial quality control (MQC) testing workflows used in the pharmaceutical manufacturing operations across the globe. It derives revenue from development, manufacturing, marketing and selling Systems and related LIMS connection software, consumables and services.